Market Overview

Speeding Drug Development for Kids and Dogs That Share Similar Cancers is Focus of Paws for a Cure Research Symposium


Veterinary and Pediatric Researchers Explore Cancer Cure

is hosting the Paws
for a Cure Research Symposium
on November 12-13, 2018 at the Merck
Research Laboratories in Boston to examine challenges and progress in
accelerating cancer drug development for shared cancers that children
and canines both get.

"Developing new cancer drugs for children has unique challenges and
progress toward better medicines has been limited," explained Ulrike
Szalay, founder and executive director, Canines-N-Kids Foundation, a
nonprofit committed to promoting research that integrates efforts for
the benefit of both kids and dogs with cancer. "Our symposium is focused
on propelling collaboration to find new drugs for these devastating
cancers that affect our children and beloved pets."

Thanks to significant support from title sponsor, the
Petco Foundation
, in partnership with the
Blue Buffalo Foundation
, the symposium will convene experts to
discuss advancing research in pediatric cancer treatments, including how
to use comparative approaches to make progress. The meeting will bring
together pediatric oncologists, veterinary oncologists, translational
research scientists in academia and in industry; pharma and biotech
professionals in preclinical research, drug development, oncology and
animal health; nonprofit and other funders.

Participants will hear from peers and experts about:

  • The state of the art in comparative and novel translational cancer
  • Ongoing preclinical, translational and clinical projects leveraging
    the canine patient model.
  • The most promising prospects for future scientific exploration,
    collaboration and funding.
  • Childhood cancer survivors and advocates' life journeys.

The Paws for a Cure Research Symposium is important because both
children and canine companions spontaneously develop a number of cancers
with remarkable similarities. The challenges inherent in designing and
implementing pediatric oncology clinical trials for limited number of
children with cancer, coupled with scant resources for conducting
research on pediatric cancers, makes finding cures difficult for the
roughly 16,000 children diagnosed in the US each year.

In addition, little pharmaceutical industry funding goes to pediatric
cancer research. As a result, only four new medications have been
approved for the treatment of pediatric cancer in the last 30 years. For
the 6 million dogs diagnosed with cancer in the US each year, the
outlook is no better. The integration of drug development in pediatric
and pet populations has great potential to accelerate the discovery of
novel, more effective, less toxic treatments for the cancers that plague
children and dogs.

The Symposium, also backed by the American Cancer Society, the Rally
Foundation (pediatric cancer), Boehringer Ingleheim Animal Health and
Applied Biomath, costs $949 for industry and $699 for academic/nonprofit
attendees. Registration information, as well as featured speakers and
topics can be found at

View Comments and Join the Discussion!